Relation of neurological soft signs to psychiatric symptoms in schizophrenia

Schizophrenia Research

Volumn 94, Issue 1-3, 2007, Pages 37-44

  Mittal, Vijay A ^a,b   Hasenkamp, Wendy ^c   Sanfilipo, Michael ^d   Wieland, Susan ^e   Angrist, Burton ^d,e   Rotrosen, John ^d,e   Duncan, Erica J ^c  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Haloperidol; Neurological Soft Signs; Schizophrenia

Indexed keywords

DEBRISOQUINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE TITRATION; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; HALOPERIDOL; HUMANS; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 34447251537     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.04.017     Document Type: Article

References (45)

1. Browne S., Clarke M., Gervin M., Lane A., Waddington J., Larkin C., and O'Callaghan E. Determinants of neurological dysfunction in first episode schizophrenia. Psychol. Med. 30 6 (2000) 1433-1441
2. Buchanan R.W., and Heinrichs D.W. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 27 3 (1989) 335-350
3. Buchanan R.W., Koeppl P., and Breier A. Stability of neurological signs with clozapine treatment. Biol. Psychiatry 36 3 (1994) 198-200
4. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., and Malaspina D. The stress cascade and schizophrenia: etiology and Onset. Schizophr. Bull. 29 4 (2003) 671-692
5. Davidson M., Losonczy M.F., Mohs R.C., Powchik P., Freed L.B., Kaminsky R., and Davis K. Methodologies for assessing central dopaminergic function: plasma and urinary homovanillic acid following debrisoquin administration. Psychopharmacol. Bull. 23 (1987) 407-410
6. Dazzan P., and Murray R.M. Neurological soft signs in first-episode psychosis: a systematic review. Br. J. Psychiatry 181 Supp 43 (2002) s50-s57
7. Duncan E., Wolkin A., and Angrist B. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Psychopharmacol. Bull. 29 3 (1993) 371-374
8. Duncanm E., Bollini A.M., Sanfilipo M., Wieland S., Angrist B., Rotrosen J., and Cooper T.B. Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls. Schizophr. Res. 8 2-3 (2006) 323-326
9. Flyckt L., Sydow O., Bjerkenstedt L., Edman G., Rydin E., and Wiesel F.-A. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res. 86 2 (1999) 113-129
10. Goodman R. Technical note: are perinatal complications causes or consequences of autism?. J. Child Psychol. Psychiatry 31 5 (1990) 809-812
11. Gorga D., Stern F.M., Ross G., and Nagler W. The neuromotor behavior of preterm and full-term children by three years of age: quality of movement and variability. J. Dev. Behav. Pediatr. 12 2 (1991) 102-107
12. Gourion D., Goldberger C., Olie J., Loo H., and Krebs M. Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. Schizophr. Res. 67 1 (2004) 23-31
13. Graybiel A.M. The basal ganglia and cognitive pattern generators. Schizophr. Bull. 23 3 (1997) 459-469
14. Guy W. ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No. ADM 76-338) (1976), U.S. Department of Health, Education & Welfare, Rockville
15. Ho B.-C., Mola C., and Andreasen N.C. Cerebellar Dysfunction in Neuroleptic Naive Schizophrenia Patients. Clinical, Cognitive, and Neuroanatomic Correlates of Cerebellar Neurologic Signs. Biol. Psychiatry 55 12 (2004) 1146-1153
16. Khadilkar V., Tudehope D., Burns Y., O'Callaghan M., and Mohay H. The long-term neurodevelopmental outcome for very low birthweight (VLBW) infants with 'dystonic' signs at 4 months of age. J. Paediatr. Child Health 29 6 (1993) 415-417
17. Kolakowska T., Williams A., Jambor K., and Ardern M. Schizophrenia with good and poor outcome: III. Neurological "soft" signs, cognitive impairment and their clinical significance. Br. J. Psychiatry 146 (1985) 348-357
18. Lachar D., Bailley S.E., Rhoades H.M., Espadas A., Aponte M., Cowan K.A., Gummatira P., Kopecky C.R., and Wassef A. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychol. Assess. 13 3 (2001) 384-395
19. Lachar D., Espadas A., and Bailley S.E. The Brief Psychiatric Rating Scale: contemporary applications. The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Instruments for Adults vol. 3 (2004), Lawrence Erlbaum Association Inc, Mahwah 153-190
20. McNeil T.F. Perinatal influences in the development of schizophrenia. In: Helmchen H., and Henn F.A. (Eds). Biological Perspectives of Schizophrenia (1987), John Wiley & Sons, New York 125-138
21. Mednick S.A., Watson J.B., Huttunen M., Cannon T.D., Katila H., Machon R., Mednick B., Hollister M., Parnas J., Schulsinger F., Sajaniemi N., Voldsgaard P., Pyhala R., Gutkind D., and Wang X. A two-hit working model of the etiology of schizophrenia. In: Lenzenweger M.F., and Dworkin R.H. (Eds). Origins and Development of Schizophrenia: Advances in Experimental Psychopathology (1998), American Psychological Association, Washington 27-66
22. Midha K.K., Hawes E.M., Hubbard J.W., Korchinski E.D., and McKay G. The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. Psychopharmacology: The Third Generation of Progress (1987), Raven Press, New York 1341-1351
23. Mittal V.A., Tessner K.D., McMillan A.L., Delawalla Z., Trotman H.D., and Walker E.F. Gesture Behavior in Unmedicated Schizotypal Adolescents. J. Abnorm. Psychology 115 2 (2006) 351-358
24. Mittal V.A., Tessner K.D., Trottman H.D., Dhruv S., Esterberg M., Simeonova D., McMillan A.L., Murphy E., Saczawa M., and Walker E.F. Movement abnormalities and the progression of prodromal symptomatology in adolescents at risk for psychotic disorders. J. Abnorm. Psychology 116 2 (2007) 260-267
25. Mittal V.A., Dhruv S., Tessner K.D., Walder D.J., and Walker E.F. The relations among putative bio risk markers in Schizotypal Adolescents: minor physical anomalies, movement abnormalities and salivary cortisol. Biol. Psychiatry 61 10 (2007) 1179-1186
26. Mohr F., Hubmann W., Albus M., Franz U., Hecht S., Scherer J., Binder J., and Sobizack N. Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia. Psychiatry Res. 121 1 (2003) 21-30
27. Moller H.-J., Bottlender R., Wegner U., Wittmann J., and Strauss A. Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatr. Scand. 102 Supp 407 (2000) 54-57
28. Neumann C.S., and Walker E.F. Neuromotor functioning in adolescents with schizotypal personality disorder: associations with symptoms and neurocognition. Schizophr. Bull. 29 2 (2003) 285-298
29. Ohaeri J.U., and Otote D.I. Subtypes and factors of schizophrenia in an acutely ill Nigerian sample. Psychopathology 36 4 (2003) 181-189
30. Prikryl R., Ceskova E., Kasparek T., and Kucerova H. Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. J. Psychiatr. Res. 40 2 (2006) 141-146
31. Quitkin F., Rifkin A., and Klein D.F. Neurological soft signs in schizophrenia and character disorders. Arch. Gen. Psychiatry 33 (1976) 845-853
32. Scheffer R.E. Abnormal neurological signs at the onset of psychosis. Schizophr. Res. 70 1 (2004) 19-26
33. Schiffman J., Ekstrom M., LaBrie J., Schulsinger F., Sorensen H., and Mednick S. Minor physical anomalies and schizophrenia spectrum disorders: a prospective investigation. Am. J. Psychiatry 159 2 (2002) 238-243
34. Shafer A. Meta-analysis of the Brief Psychiatric Rating Scale factor structure. Psychol. Assess. 17 3 (2005) 324-335
35. Smith R.C., and Kadewari R.P. Neurological soft signs and response to risperidone in chronic schizophrenia. Biol. Psychiatry 40 10 (1996) 1056-1059
36. Soorani-Lunsing R., Hadders-Algra M., Olinga A., Huisjes H., et al. Is minor neurological dysfunction at 12 years related to behaviour and cognition?. Dev. Med. Child Neurol. 35 4 (1993) 321-330
37. Spitzer R.L., Williams J.B.W., Gibbon M., and First M.B. Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P, 4/1/88) (1988), Biometrics Research Department, New York State Psychiatric Institute
38. Tosato S., and Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr. Opin. Psychiatry 18 3 (2005) 285-288
39. Venkatasubramanian G., Latha V., Gangadhar B., Janakiramaiah N., Subbakrishna D., Jayakumar P., and Keshavan M. Neurological soft signs in never-treated schizophrenia. Acta Psychiatr. Scand. 108 2 (2003) 144-146
40. Walker E.F., and Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 104 4 (1997) 667-685
41. Walker E.F., Lewine R.R., and Neumann C. Childhood behavioral characteristics and adult brain morphology in schizophrenia. Schizophr. Res. 22 2 (1996) 93-101
42. Walker E., Lewis N., Loewy R., and Palyo S. Motor dysfunction and risk for schizophrenia. Dev. Psychopathol. 11 3 (1999) 509-523
43. Whitty P., Clarke M., Browne S., McTigue O., Kamali M., Feeney L., Lane A., Kinsella A., Waddington J., Larkin C., and O'Callaghan E. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol. Med. 33 8 (2003) 1479-1484
44. Wolkin A., Brodie J.D., Barouche F., Rotrosen J., et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry 46 5 (1989) 482-484
45. Woods B.T., Kinney D.K., and Yurgelun-Todd D. Neurologic abnormalities in schizophrenic patients and their families: I. Comparison of schizophrenic, bipolar, and substance abuse patients and normal controls. Arch. Gen. Psychiatry 43 7 (1986) 657-663